Literature DB >> 2522879

T helper cells grown with hapten-modified cultured Langerhans' cells produce interleukin 4 and stimulate IgE production by B cells.

C Hauser1, C M Snapper, J Ohara, W E Paul, S I Katz.   

Abstract

Hapten-specific CD4+ T helper (Th) lines generated by repeated stimulation with hapten-modified, cultured Langerhans' cells (cLC) release interleukin (IL 4) (B cell stimulatory factor 1) but not detectable IL 2 into the culture media. The growth of Th cells in response to hapten-modified cLC was inhibited by an anti-IL 4 monoclonal antibody (mAb) but not by mAb to either IL 2 or the p55 chain of the IL 2 receptor. Furthermore, these cells could be stimulated to proliferate by concanavalin A and IL 1. These results indicate that IL 4 is the autocrine growth factor for these Th lines and that IL 1 plays a critical role in their growth. The Th cells exhibited 1,500-10,000 high-affinity IL 4 receptors cell. When cultured with syngeneic, hapten-modified, small resting B cells, Th cells caused specific IgE production of up to 20 ng/10(4) B cells. Thus, IL 4 producing Th lines appear to result from their selective stimulation by cLC, suggesting that T cell responses elicited in this way profoundly influenced the B cell isotype pattern.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2522879     DOI: 10.1002/eji.1830190205

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  15 in total

1.  IgG subclass responses to Theiler's murine encephalomyelitis virus infection and immunization suggest a dominant role for Th1 cells in susceptible mouse strains.

Authors:  J D Peterson; C Waltenbaugh; S D Miller
Journal:  Immunology       Date:  1992-04       Impact factor: 7.397

Review 2.  Induction of T helper cell subsets.

Authors:  M Röcken; K M Müller; C Hauser
Journal:  Springer Semin Immunopathol       Date:  1992

3.  Dissolving microneedle delivery of nanoparticle-encapsulated antigen elicits efficient cross-priming and Th1 immune responses by murine Langerhans cells.

Authors:  Marija Zaric; Oksana Lyubomska; Candice Poux; Mary L Hanna; Maeliosa T McCrudden; Bernard Malissen; Rebecca J Ingram; Ultan F Power; Christopher J Scott; Ryan F Donnelly; Adrien Kissenpfennig
Journal:  J Invest Dermatol       Date:  2014-09-22       Impact factor: 8.551

4.  Interleukin 2 therapy in severe atopic dermatitis.

Authors:  K H Hsieh; C C Chou; S F Huang
Journal:  J Clin Immunol       Date:  1991-01       Impact factor: 8.317

Review 5.  Atopic dermatitis results in intrinsic barrier and immune abnormalities: implications for contact dermatitis.

Authors:  Julia K Gittler; James G Krueger; Emma Guttman-Yassky
Journal:  J Allergy Clin Immunol       Date:  2012-08-28       Impact factor: 10.793

6.  Antigen-specific modulation of murine IgE and IgG2a responses with glutaraldehyde-polymerized allergen is independent of MHC haplotype and Igh allotype.

Authors:  K T Hayglass; W Stefura
Journal:  Immunology       Date:  1991-05       Impact factor: 7.397

7.  Long-lived reciprocal regulation of antigen-specific IgE and IgG2a responses in mice treated with glutaraldehyde-polymerized ovalbumin.

Authors:  K T Hayglass; R S Gieni; W P Stefura
Journal:  Immunology       Date:  1991-08       Impact factor: 7.397

8.  Epidermal and splenic antigen-presenting cell function in a retrovirally induced murine immunodeficiency syndrome (MAIDS).

Authors:  A Cerny; S Izui; J H Saurat; F A Waldvogel; H C Morse; C Hauser
Journal:  Arch Dermatol Res       Date:  1992       Impact factor: 3.017

9.  Examination of lymphokines induced in mice following immunization with recombinant simian virus 40 large tumor antigen.

Authors:  R K Bright; M H Shearer; R C Kennedy
Journal:  Cancer Immunol Immunother       Date:  1995-03       Impact factor: 6.968

10.  The effect of cyclosporin A, FK506, and rapamycin on the murine chronic graft-versus-host response--an in vivo model of Th2-like activity.

Authors:  R V Bundick; R I Craggs; E Holness
Journal:  Clin Exp Immunol       Date:  1995-03       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.